SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors digest the company's recent earnings, with some highlighting a narrower-than-expected loss and revenue growth. The community is actively discussing the potential impact of Rivian's AI and robotics initiatives, as well as upcoming catalysts like Autonomy Day. Despite some skepticism, optimism is fueled by Amazon's significant stake and hopes for the R2 model's success.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Enthusiasm is building around $SLAP, with community members expressing bullish sentiment and highlighting its resilience in the current market. There's a strong sense of camaraderie among holders, who frequently use terms like $WAGMI (we're all gonna make it) and celebrate the project's unique branding and community engagement.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending as investors discuss potential strategic scenarios, including a takeover or a new shipping supercycle driven by global trade shifts. Community discussions revolve around the company's valuation, dividend prospects, and potential for a short squeeze amid rising freight rates and institutional buying. Several analysts are weighing in with divergent views on the outlook.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending with community members discussing its potential trajectory amidst broader crypto market movements. Some traders are anticipating a dump, while others are optimistic about a future pump, possibly fueled by Elon Musk. General sentiment appears mixed as some express concerns about Dogecoin's historical price action.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending due to community discussion around high borrow fees and potential short squeeze, as some retail investors report difficulty lending shares. Traders are debating the impact of dark pool trading and synthetic short positions, suggesting shorts are trapped and retail accumulation is key. Overall, the community is closely watching borrow rates, float size, and potential for a squeeze amid unusual trading activity.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer's pursuit of Metsera has intensified, with the company filing a second lawsuit against Novo Nordisk amidst a heated bidding war, driving significant community discussion around the potential acquisition's impact on the competitive landscape of obesity therapeutics. Community members are debating whether Pfizer is overpaying and if the acquisition aligns with their long-term strategy, especially given the existing competition in the weight loss market; at the same time, there's also discussion of Michael Burry's new position in PFE.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

ADUR is trending as the company progresses towards commissioning its pilot plant, aiming to validate its technology for converting waste into valuable resources. Community discussions revolve around the potential of Aduro's technology and its licensing model, with some comparing it favorably to competitors in the clean tech sector. Additionally, the stock's social media presence and marketing efforts are being closely watched.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending amid community discussion around its potential for growth and recent options activity. Some investors express frustration with the stock's recent performance despite analyst ratings, while others remain confident in the long-term vision and potential acquisitions led by Brad Jacobs. The community is actively discussing entry and exit points, with many expressing a bullish outlook.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending amid mixed sentiment, with community members debating whether recent price movements are sustainable or just a "dead cat bounce." Some traders are pointing to potential catalysts like staking rewards and broader crypto market trends, while others warn of a possible downturn and label the token a "sucker coin."

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

MTSR is trending due to a bidding war between PFE and NVO to acquire the company and its next-generation obesity pipeline. Community members discuss which company will ultimately win the deal and the potential implications for the broader obesity drug market. Some traders believe a competing bid could still emerge, further driving up the acquisition price.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Aurinia (AUPH) Run Higher on Rising Earnings Estimates?

Aurinia Pharmaceuticals (AUPH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Q4 EPS Estimate for Aurinia Pharmaceuticals Cut by Analyst

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) - Equities research analysts at HC Wainwright decreased their Q4 2026 earnings estimates for Aurinia Pharmaceuticals in a research...

Leerink Partnrs Issues Positive Outlook for AUPH Earnings

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) - Analysts at Leerink Partnrs upped their Q1 2026 earnings per share estimates for Aurinia Pharmaceuticals in a note issued to...

Aurinia Pharmaceuticals (NASDAQ:AUPH) Issues Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) (TSE:AUP) released its quarterly earnings data on Tuesday. The biotechnology company reported $0.23 earnings per share for the quarter, beating...

Aurinia Pharmaceuticals' (AUPH) Sector Perform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $15.00 price target (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday...

Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +43.75% and +7.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress. Financial...

<ul class="summary-bullets"><li>The development comes shortly after George Tidmarsh took a potshot against Aurinia Pharma’s kidney inflammation drug in a now-deleted LinkedIn post.</li><li>In announcing his resignation, he reportedly alleged that a new FDA drug approval program “injected politics into the drug review program, superseding decisions based on science.”</li><li>Retail traders on Stocktwits saw Tidmarsh’s Aurinia attack as a “stock manipulation” move.</li></ul>Aurinia Pharmaceuticals, Inc. (AUPH) was among the top five trending equities on Stocktwits late Sunday as retail traders discussed reports regarding developments following a lawsuit filed by the company against Dr. George Tidmarsh, who served as the director of the FDA’s Center for Drug Evaluation and Research (CDER) and was appointed to the post on an interim basis in late July.<h2 class="st-heading-2">Tidmarsh’s Rapid Exit</h2>A New York Times report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nytimes.com/2025/11/02/health/fda-drug-unit-chief.html">stated</a> on Sunday that Tidmarsh said in an interview that he was placed on administrative leave on Friday after he raised concerns over the legality of a new program that was put in place to approve drugs rapidly, reasoning that the new program “injected politics into the drug review program, superseding decisions based on science.”The Department of Health and Human Services (HHS) placed him on leave, pending the outcome of an investigation. Tidmarsh claimed that the move may have been a preemptive one to his offer to resign in protest against the new program.In the Times interview, Tidmarsh said he didn’t want to work in a toxic environment, attributing it to&nbsp;Dr. Vinay Prasad, who returned as chief medical and scientific officer&nbsp;at the Center for Biologics Evaluation and Research (CBER) and also oversaw vaccines and gene therapies.&nbsp;Tidmarsh took exception to an October FDA announcement that it would&nbsp;approve a slate of drugs in record time. “The effort was going to basically change the entire paradigm of the legal underpinnings of drug approvals that have for decades supported the actions on the safety and effectiveness of drugs,” he said. “There was insufficient legal support for what they wanted to do, and so I didn’t agree.”<h2 class="st-heading-2">The Aurinia Connection</h2>HHS’s move came after Kevin Tang, the chair of Aurinia Pharma, filed a complaint against Tidmarsh on Sunday, alleging that the latter has acted out of his “longstanding personal vendetta against Tang, STAT&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/11/02/fda-george-tidmarsh-regulator-kevin-tang/">reported</a>. Tidmarsh previously served as CEO of La Jolla, with Tang serving as the company’s chair at that time.Tidmarsh claimed in a LinkedIn post, which has since been retracted, that companies working on lupus nephritis therapies haven‘t conducted post-approval studies to “demonstrate a benefit on hard clinical endpoints,”&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.biospace.com/fda/cder-director-singles-out-aurinias-drug-in-questioning-reliance-on-surrogate-endpoints">according</a> to Biospace.Posting on LinkedIn on Sept. 30, Tidmarsh said, “We have approved drugs with significant toxicity like vocolosporin [Lupkynis’ active ingredient] that has not been shown to provide a direct clinical benefit for patients. He also stated that “for some diseases such as lupus nephritis, companies have not run trials to demonstrate a benefit on hard clinical endpoints.”Lupkynis is Aurinia’s FDA-approved oral medication for treating lupus nephritis, or kidney inflammation caused by an autoimmune disorder. It was approved in January 2021. Responding to the post, Aurinia said it “stands behind the favorable benefit/risk profile” of Lupkynis. For the six months ended June, the drug fetched $126.5 million in revenue for Aurinia, marking a 23% year-over-year increase. It accounted for 96% of the company’s revenue for the period.In a post on X, STAT’s Adam Feuerstein<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/adamfeuerstein/status/1985132443901259898"> stated&nbsp;</a>that the lawsuit filed by Aurinia also accused Tidmarsh of extorting money from American Labs, a private company owned by Tang that supplies ingredients for a thyroid medicine. Tidmarsh reportedly directed the FDA to ya nk thyroid drugs off the market to hurt American Labs.<h2 class="st-heading-2">What Retail’s Saying</h2>On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharma stock&nbsp;</a>remained ‘bullish’ as of late Sunday, and the retail chatter also stayed high. The message volume over the seven days, ending late Sunday, climbed about 300%.&nbsp;A bullish watcher called Tidmarsh’s action “stock manipulation.” Another user also shared a similar view. “I'm almost certain Tidmarsh wrote this post to drive down the stock price. He bought Aurinia shares at a low price. Now there's an investigation, so he preferred to resign,” they said.<stembedurl>https://stocktwits.com/RetirednCali/message/634634317</stembedurl><stembedurl>https://stocktwits.com/Gamaret/message/634634040</stembedurl>Aurinia Pharma stock is up about 47% this year. Although the stock shed 4% in the two days after Tidmarsh’s post, it rallied 8.66% on Friday.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/colgate-palmolive-stock-still-finds-bullish-retail-support-after-signaling-consumer-fatigue/cL2ZoWtR3yn">Colgate-Palmolive Stock Still Finds Bullish Retail Support After Signaling Consumer Fatigue With Sluggish Outlook</a>

Young female scientist working in laboratory (Representative image courtesy of Solskin via Getty Images)

FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’

Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science.

Equity

Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science.


Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS (voclosporin) at the...

Aurinia Pharmaceuticals on Monday pushed back on criticism of its lupus drug Lupkynis (voclosporin) by a top FDA official who had raised questions about the medicine’s clinical benefit in a LinkedIn post that has since been deleted.Shares of Aurinia tumbled 16% to $11.06, marking their worst day since February 2024, before recovering 4% in after-hours trading to $11.51.In a statement, Aurinia reiterated its positive outlook for Lupkynis, stating that it has an established benefit–risk profile. Aurinia highlighted that the drug was granted full FDA approval in January 2021 following the AURORA 1 study, and received additional approval in April 2024 based on data from the AURORA 2 study, which demonstrated its efficacy and safety over a three-year period.The selloff followed a post by George Tidmarsh, director of the FDA’s drug center, who said Lupkynis “has not been shown to provide a direct clinical benefit for patients.” His comments were part of a broader discussion about the agency’s use of surrogate endpoints, which are biological measures used to accelerate drug approvals, that he said had led to both “notable successes and failures.”The post drew widespread attention not only for its criticism of a specific drug and company, something regulators almost never do publicly, but also for its choice of platform.&nbsp;Soon after media reports surfaced, Tidmarsh deleted the post and clarified that his comments were “personal views” that “do not reflect those of the FDA or HHS,”&nbsp; adding that all official communications would continue to be made through formal agency channels.On Stocktwits, retail sentiment for Aurinia was ‘extremely bullish’ amid a&nbsp;whopping 10,040% surge in 24-hour message volume.One user said the stock’s decline wasn’t surprising, describing it as a healthy pullback after a strong run that could set up the next move higher.<stembedurl>https://stocktwits.com/Itsagame999/message/630423873</stembedurl>Other users expressed frustration with the company’s response, saying they had expected a stronger reaction and were disappointed by what they described as a brief, generic statement, with one adding they had lost $70,000 on the drop.<stembedurl>https://stocktwits.com/timfris/message/630421172</stembedurl><stembedurl>https://stocktwits.com/Dallas9/message/630420635</stembedurl><a href="https://stocktwits.com/symbol/AUPH">Aurinia’s stock</a> has risen 23.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aurinia’s stock (AUPH) has risen 23.2% so far in 2025. (Photo credit: Getty Images)

Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery

The company reiterated its confidence in Lupkynis’ long-term efficacy and safety following its approval and the submission of supplementary data.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc